206786 Liver Disease: Policy Impact and Need

Wednesday, November 11, 2009: 8:30 AM

Susan C. Robinson, MPA , Program, American Liver Foundation, New York, NY
Pamela Gleason , Mid-Atlantic Division, American Liver Foundation, Philadelphia, PA
Indhira Blackwood, MPA , Program, American Liver Foundation, New York, NY
Emily Watson, MPH , Program, American Liver Foundation, New York, NY
Katherine Cline , Georgia Division, American Liver Foundation, Atlanta, GA
The complexity of liver disease -- widespread lack of awareness of liver diseases, their risk factors and prevention strategies; the often unrealized onset leading to often-too-late diagnosis; stigma and discrimination faced by patients; need for well-coordinated medical care and social services; need for more effective treatments and cures; significant current and future financial impact on individuals, businesses and government, and lack of a national data surveillance system -- makes necessary a comprehensive, multi-dimensional public health policy agenda that addresses patient services and research that focus on maximizing health outcomes and the elimination of liver disease.

There are 100 liver diseases. An estimated 30 million individuals it he US have liver disease. An estimated 5.4 million are infected with viral hepatitis and 65,000 will be newly infected this year. Chronic viral hepatitis is the leading cause of liver cancer and liver transplantation; it will cause an estimated 15,000 deaths. The projected cost of viral hepatitis is more than $85 billion. The total impact of all liver diseases is exponentially greater. The American Liver Foundation directs local, state and federal advocacy efforts that address patient services and research needs to decrease liver disease impact.

A comprehensive public health policy agenda that addresses the many and significant issues affecting liver disease patients and the general public will identify meaningful solutions that improve the lives of people affected by liver disease and prevent devastating future public health impact. This session will discuss ALF's collaborative advocacy efforts and outcomes.

Learning Objectives:
(1) Describe the needs of people with liver disease (2) Discuss the policy impact on people with liver disease (3) Discuss ALF's policy priorities to improve the lives of people affected by liver disease

Keywords: Policy/Policy Development, Disease Prevention

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: As Division Vice President of the Mid-Atlantic Division, I oversee and conduct education programs.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.